Myriad™ Matrix Shows 95% Success Rate in High-Risk Limb Salvage Surgery, New Study Reports

A new large-scale prospective clinical study has demonstrated exceptional outcomes for AROA Biosurgery's Myriad Matrix™ in complex lower limb reconstruction procedures, offering new hope for patients at risk of amputation while potentially delivering significant cost savings for healthcare providers.

The groundbreaking study, published in Plastic and Reconstructive Surgery – Global Open, evaluated 130 complex lower limb defects across 120 patients between May 2022 and April 2023. Notably, 95% of enrolled patients presented with at least one risk factor for lower limb amputation, with more than half (55%) exhibiting three or more predictive risk factors.

Remarkable Clinical Outcomes

The study revealed that Myriad Matrix™ and Myriad Morcells™ achieved complete tissue coverage and fill within 30 days following a single application. Significantly, no infections or complications were reported throughout the study period, a remarkable achievement given the high-risk patient population.

"I've been using AROA's Myriad products for several years now and have seen the difference Myriad can make in my own patient population," stated Dr. John Lawlor, the study's lead investigator and experienced Foot and Ankle Surgeon based in Florida. "It's very encouraging to see this large study published, quantifying the significant positive impact to patients."

Substantial Cost Benefits

Beyond its clinical efficacy, the study highlighted potential cost advantages, demonstrating an estimated cost difference of up to 195% compared to other commercially available dermal matrices in inpatient lower extremity reconstruction. This finding suggests significant potential for healthcare cost reduction while maintaining high standards of care.

Market Impact and Future Implications

The study represents the first publication from AROA's ongoing Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR) and carries substantial implications for the field of limb salvage surgery. With lower limb amputation associated with a sobering 5-year mortality rate of approximately 50%, effective limb preservation strategies are crucial for patient outcomes.

Brian Ward, Founder and CEO of AROA Biosurgery, emphasized the market potential: "With a total addressable market of $225 million USD for lower limb procedures alone, this represents a considerable opportunity for AROA." The study's findings could significantly influence treatment protocols for complex lower limb reconstruction, particularly given the demonstrated combination of clinical efficacy and cost-effectiveness.